ALERTS100%to10000%GAIN
2 years ago
AnPac Bio-Medical Science Co Ltd
additional information aboutADR
(ANPC)
TradeSet AlertAdd to Watchlist
Biotechnology
NASDAQ
$0.2548
Today's Change
$0.0047(+1.88%)
ADR Ratio
1:1
Bid/Size
$0.2547/1
Ask/Size
$0.2597/6
Today's Volume
1.1M
Today's Range
$0.25$0.2699
52 Week Range
$0.2022$4.01
Today's Open
$0.26
Previous Close
$0.2501
Quote as of 1:09 PM ET, 08/29/2022
You may be charged fees by the Bank that custodies this ADR. Read More about ADR pass-through fees.
This stock may be available for trading through a Schwab Global Account. Learn More
Margin Requirements
Chart
zoom
toggle
Show events
-3.18 (-92.57%)
Disclosures
Technicals
toggle
Indicators Table
Beta (5 Year) On Balance Volume RSI (14-Day)
-- Trending Higher 47.34
Averages Table
10-Day Average Volume 12,972,280
90-Day Average Volume 2,199,015
20-Day Moving Average $0.26
50-Day Moving Average $0.28
200-Day Moving Average $0.65
Historical Volatility (10 Day) 138.07%
Previous analysis slide
Trend Analysis
ANPC appears to be rallying within a longer-term bearish trend, driving its MACD above the signal line. However, shares remain below a declining 200-day moving average, signifying that the dominant trend remains lower. Comparative Relative Strength analysis shows that this issue is lagging the S&P 500.
As of 1:09 PM ET Monday, 08/29/2022
Momentum
Momentum for ANPC is strongly bearish. The 14-period Slow Stochastic oscillator is below 20, the level which many analysts call oversold. This means that investors have been actively selling shares and driving the price lower.
As of 1:09 PM ET Monday, 08/29/2022
Volume
Today's volume is on track to be lighter than usual, with 1,087,493 shares having traded so far. The On Balance Volume indicator (OBV) is bullish. The slope of the indicator is positive and suggests that buyers are presently more active than sellers.
As of 1:09 PM ET Monday, 08/29/2022
Volatility
Bollinger Bands® use standard deviation of the closing price around a moving average to measure volatility. The Bollinger Bands® are presently wider than usual, as a result of greater than normal volatility that accompanied the recent price move. Events such as this may precede a pause or reversal in the near term trend.
As of 1:09 PM ET Monday, 08/29/2022
Next analysis slide
Disclosures
Expected Earnings
zoom
toggle
Upcoming Earnings
Chart currently unavailable
Next Earnings Announcement
09/02/2022
Time of Release
After Market Close
Consensus Estimate (Q2 2022)
--
Historical Earnings
Chart currently unavailable
Non-GAAP (Q1 2022)
--
Consensus Estimate (Q1 2022)
--
Revenue (TTM)
$2.60M
Price/Earnings (TTM)
--
Forward P/E
--
Price to Earnings/Growth (PEG)
--
Disclosures
Dividends
zoom
toggle
The security does not currently pay a dividend
Disclosures
Peers & Ratios Comparison
zoom
toggle
Overview Table
ANPC BRTX DFFN YTEN CLSN
Company Name AnPac Bio-Medical Science Co Ltd BioRestorative Therapies Inc Diffusion Pharmaceuticals Inc Yield10 Bioscience Inc Celsion Corp
Schwab Equity Rating®* Opens a new window with more information about Schwab Equity Rating NC
Opens a new window with more information about Schwab Equity Rating NC
Opens a new window with more information about Schwab Equity Rating NC
Opens a new window with more information about Schwab Equity Rating NC
Opens a new window with more information about Schwab Equity Rating NC
Last Price $0.25 $3.32 $6.65 $3.16 $2.22
Market Cap $6M $12M $13M $15M $16M
Price / Earnings (TTM) -- -- -- -- --
Annual Dividend Yield -- -- -- -- --
EPS Growth Forecast - 3-5 Year -- -- -- -- --
Net Profit Margin -595.09% -34,044.71% -- -2,450.00% -5,229.82%
*Schwab Equity Rating based on data as of 08/26/2022 market close.
**Not Currently Rated By Reuters.
Statements
zoom
toggle
Converted Values in $USD
Statements Result Table
Balance Sheet
(Fiscal Year Ending in December)
Annual
Trend
2021
12/31/2021
2020
12/31/2020
2019
12/31/2019
2018
12/31/2018
2017
12/31/2017
Total Current Assets
Chart for Total Current Assets annual trend. 3.70 3.26 3.18 3.03 2.72
Total Assets
Chart for Total Assets annual trend. 10.62 7.64 7.61 7.67 9.10
Total Current Liabilities
Chart for Total Current Liabilities annual trend. 9.90 6.67 9.51 10.39 5.35
Total Debt
Chart for Total Debt annual trend. 5.31 1.26 5.54 3.77 1.89
Total Liabilities
Chart for Total Liabilities annual trend. 11.33 7.19 9.90 10.93 7.66
Total Equity
Chart for Total Equity annual trend. (0.71) 0.45 (2.29) (3.26) 1.45
Total Liabilities & Shareholders' Equity
Chart for Total Liabilities & Shareholders' Equity annual trend. 10.62 7.64 7.61 7.67 9.10
Values are in Millions, except for per share data.
Years are Fiscal Years. () = Negative
Disclosures
Ratings
toggle
Schwab Equity Rating®
No rating provided by Schwab.
MSCI LogoESG RatingNo rating provided by MSCI.Learn more about MSCI’s ratings methodologies
Morning Star LogoNo Morningstar Rating available.
Credit Suisse LogoNo rating provided by Credit Suisse.View all Credit Suisse Research Reports
Thomson Reuters Logo
As of 03/31/2020
SellUnderperformHoldSelected Value:OutperformBuy
Reuters Investment Profile
Reuters maintains a current price target of $18.00 for ANPC.
CFRA LogoNo ranking provided by CFRA
Argus LogoNo rating provided by Argus
Market Edge LogoNo rating provided by Market Edge
1 Ratings are specific to each type of security. Equities display Schwab Equity Ratings®, ETFs & Closed End Funds display a link to Morningstar ratings, Mutual Funds display Morningstar ratings, and Fixed Income displays S&P followed by Moody's ratings.
Disclosures
ETFs Holding This Company
toggle
No ETFs Available
Stay Connected™
toggle
Settings
current slide 1
Reuters Investment Profile Report now available
On Aug 26, 2022 Reuters released an updated analyst report.
View Report
Q2 2022 Earnings Expected 09/02/2022
Price Crossed Below 50-Day Moving Average 08/26/2022
Disclosures
Company Profile
zoom
toggle
Business Summary
AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China.
Show More
Website
www.anpacbio.com
makinezmoney
2 years ago
$ANPC: NOw at $0.54....... coming to sub $0.20
Thats where this is buy.
I know its FDA approved.......... then its a nice long term hold
Waiting to get in.
AnPac Bio-Medical Science Co., Ltd. is a China-based biotechnology company focused on early cancer screening and detection. The Company markets and sells multi-cancer screening and detection test that uses cancer differentiation analysis (CDA), technology and its cancer-detection device or CDA device. In addition to early cancer screening and detection, its CDA technology assists physicians in cancer diagnosis, prognosis and recurrence. Its CDA technology provides a platform on which it has developed cancer screening and detection test using its CDA technology, or CDA test, and its CDA device. Its CDA technology focuses on biophysical properties in human blood. The Company have established two clinical laboratories in China and one clinical laboratory in the United States.
www.anpac.cn
Ranked #1 GLobally in Multi-Cancer Screening
Leading US Market Analysis and Research Firm Ranked AnPac Bio Globally Number One in Multi-Cancer Screening and Detection Test Volume
PHILADELPHIA, Jan. 25, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced today that Frost & Sullivan Company (“Sullivan”), a leading and well-known US market analysis and research firm has ranked AnPac Bio globally as number one in worldwide multiple cancer screening and detection volume in a recent research report (based on data accumulated through the end of 2020), which included next generation cancer screening and detection technologies, including circulating tumor cells (CTCs), circulating-DNA (CT-DNA), exosome, cancer differentiation analysis (CDA), mRNA, and other emerging technologies. Specifically, for next generation cancer screening and detection, the Sullivan research report ranked AnPac Bio globally as number one in total volume of multi-cancer screening and detection, with 216,600 detection tests, while GRAIL Company was ranked globally number two with 135,100 detection tests. In the category of volume of commercial multi-cancer tests (for next generation cancer screening and detection), AnPac Bio was ranked global number one as well with 172,900 detection tests.
Since 2010, AnPac Bio has been a thought leader, major innovator, and champion of multi-cancer testing. The Company has made significant contributions to the ideas, technology development and practice in this field, as recorded and evidenced by its multiple patent filings going back over ten years, announcement in 2014 with the successful development and launch of a novel technology capable of detecting 16 types of cancer diseases, and publications of four technical papers at 2015 ASCO meeting.
Dr. Chris Yu, CEO and Chairman of AnPac Bio commented: “We are very pleased with this significant global number one ranking, which signifies AnPac Bio as a global leader and the most accepted player in the field of multi-cancer screening and detection. The increasing volume in multi-cancer screening and detection indicates that our multi-cancer vision is clearly winning. We are even more excited by the progress in our multi-cancer screening platform and that more and more experts and customers are embracing this novel and great idea. We will work very hard to ensure that our multi-cancer screening and detection technology will continue to be adopted by the population and will save millions of lives.”
About AnPac Bio
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 150 issued patents as of September 30, 2021. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. According to Frost & Sullivan, AnPac Bio is number one in total volume of multi-cancer screening and detection, with 216,600 detection tests. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.
For more information, please visit: https://www.Anpacbio.com .
For investor and media inquiries, please contact:
Company:
Phil Case, Marketing and Investor Relations
Phone: +1-267-810-6776 (US)
Email: phil_case@AnPacbio.com
Investor Relations:
Ascent Investor Relations LLC
Tina Xiao, President
Phone: +1-917-609-0333 (US)
Email: tina.xiao@ascent-ir.com
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," “target,” “aim,” “predict,” “outlook,” “seek,” “goal” “objective,” “assume,” “contemplate,” “continue,” “positioned,” “forecast,” “likely,” "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; our relationship with our major business partners and customers; and the duration of the coronavirus outbreaks and their potential adverse impact on the economic conditions and financial markets and our business and financial performance, such as resulting from reduced commercial activities due to quarantines and travel restrictions instituted by China, the U.S. and many other countries around the world to contain the spread of the virus. Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Primary Logo
News Provided by GlobeNewswire via QuoteMedia
GO $ANPC
The GidDy uP Kid
2 years ago
ANPC... Just last month (March 03, 2022)... GidDy uP ANPC...
AnPac Bio's Bio-Chip Subsidiary, Changwei System Technology Co., Ltd., Receives Independent Valuation and Approval from the Board to Explore Strategic Alternatives
PHILADELPHIA, March 03, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced today that its fully owned biochip subsidiary, Changwei System Technology (Shanghai) Co., Ltd. (“Changwei”), was recently evaluated and appraised by China Alliance Appraisal (Shanghai) Co. Ltd., an independent company that is certified and licensed by the China Appraisal Society under the Ministry of Finance and is one of the top 10 appraisers in China by revenue. China Alliance Appraisal, Co., Ltd. provided a certified written appraisal report which valued Changwei at RMB 578 million (approximately USD $90 million based on the current exchange rate). An appraisal is an opinion about the approximate value of a company and is not a guarantee that any transaction may be completed based on that appraised value or at all. The appraisal was performed following the recent approval from the board of directors of AnPac Bio to explore strategic alternatives for Changwei, including a potential strategic investment, to maximize shareholder value for the Company.
Changwei was founded in 2011 and has since focused on the design, R&D, and testing of novel, specialty bio-integrated circuit (IC) chips for life science applications. The team consists of a group of IC experts and engineers from IC and IC packaging companies such as Micron Technologies, Motorola, Semiconductor Manufacturing International Corporation, and Amkor. Changwei is currently developing biochips for in vitro diagnostics (IVD) applications and the biochip currently used in Anpac Bio’s Cancer Differentiation Technology (CDA) platform for cancer screening and detection, which has already been commercialized and is in volume production. In addition, in 2021, Changwei began development of a new biochip for AnPac Bio JV’s novel cancer treatment. Recently, Changwei signed a letter of intent with a life science company, under which Changwei will work on a new biochip for an automatic drug injection medical device for diabetes patients.
Dr. Chris Yu, CEO and Chairman of AnPac Bio commented: “We are very pleased with the progress of our IC chip subsidiary, including our novel IC chip for multi-cancer screening and detection applications. In addition to helping AnPac Bio in cancer screening, Changwei’s talent, IP, knowledge and experience may also be of benefit to life science companies to develop new and novel products involving Changwei-designed biochips.”
There can be no assurance that the strategic review process will result in any strategic alternative, or any assurance as to its outcome or timing. AnPac Bio has not set a timetable for completion of the review process and does not intend to disclose developments related to the process unless and until the Board otherwise determines that further disclosure is appropriate or required.
About AnPac Bio
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 150 issued patents as of September 30, 2021. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. According to a report by Frost & Sullivan, AnPac Bio ranked first globally in multi-cancer screening and detection test sample volume (accumulative to January 2021). AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.
For more information, please visit: https://www.Anpacbio.com .
For investor and media inquiries, please contact:
Company:
Phil Case, Marketing and Investor Relations
Phone: +1-267-810-6776 (US)
Email: phil_case@AnPacbio.com
Investor Relations:
Ascent Investor Relations LLC
Tina Xiao, President
Phone: +1-917-609-0333 (US)
Email: tina.xiao@ascent-ir.com
Register for real-time alerts, custom portfolio, and market movers
D-bol
2 years ago
Junno1616
2 years ago
ErnieBilco
2 years ago
TheFinalCD
2 years ago
Hot Features
Premium
